Skyepharma (SKP)

70.00p
   
  • Change Today:
      0.13p
  • 52 Week High: 87.00p
  • 52 Week Low: 31.00p
  • Currency: UK Pounds
  • Shares Issued: 23.94m
  • Volume: 7,505
  • Market Cap: £16.76m
  • RiskGrade: 729

Skyepharma Overview

Skyepharma is a drug research and development company with a leading drug deliveries technology business, specialising in oral, topical, inhalable and injectable delivery systems.

1 Day Chart

1 Day Chart

6 Month Chart

6 Month Chart

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn 17.8% 10.0%
ROCE 33.3%  
Latest F'cast
P/E 36.8 3.5
PEG n/a n/a
Pr/Revenue 0.3 0.3
Pr/Book n/a  
Latest F'cast
Revenue -5.0% -4.7%
PBT n/a n/a
EPS -93.6% 936.8%
DPS n/a n/a

Skyepharma Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-07 41.60 (23.70) (279.10)p n/a n/a n/a n/a 0.0%
31-Dec-08 62.20 (28.10) (1.70)p n/a n/a n/a n/a 0.0%
31-Dec-09 55.90 (0.90) (6.00)p n/a n/a n/a n/a 0.0%
31-Dec-10 58.10 6.50 29.60p 1.1 n/a n/a n/a 0.0%
31-Dec-11 55.20 (1.00) 1.90p 18.8 n/a -94% n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Skyepharma Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-12 52.62 5.25 19.70p 3.6 0.0 +937% n/a 0.0%
31-Dec-13 59.16 7.81 29.75p 2.4 0.0 +51% n/a 0.0%

Copyright © 2012 FactSet Research Systems Inc. All rights reserved.

Skyepharma Company Announcements

Result of AGM 16-May-2012 13:51 RNS
Interim Management Statement 16-May-2012 07:00 RNS
Director/PDMR Shareholding 11-May-2012 10:35 RNS

Latest Skyepharma Director Deals

Traded Action Notifier PriceAmountValue
03-May-12 Transfer From Peter Grant 0.000p 160 £0.00
03-May-12 Buy Peter Grant 78.00p 160 £124.80
30-Mar-12 Transfer From Peter Grant 0.000p 390 £0.00

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

Skyepharma Market Data

Currency UK Pounds
Share Price 70.00p
Change Today 0.13p
% Change 0.18 %
52 Week High 87.00p
52 Week Low 31.00p
Volume 7,505
Shares Issued 23.94m
Market Cap £16.76m
RiskGrade 729

Skyepharma Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
19.15% above the market average19.15% above the market average19.15% above the market average19.15% above the market average19.15% above the market average
19.15% above the sector average19.15% above the sector average19.15% above the sector average19.15% above the sector average19.15% above the sector average
Price Trend
97.98% above the market average97.98% above the market average97.98% above the market average97.98% above the market average97.98% above the market average
96.43% above the sector average96.43% above the sector average96.43% above the sector average96.43% above the sector average96.43% above the sector average
Income Not Available
Growth
83.01% below the market average83.01% below the market average83.01% below the market average83.01% below the market average83.01% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average

Skyepharma Dividends

No dividends found

Trades for 25-May-2012

Time Volume / Share Price
14:46 165 @ 68.46p
11:35 1,112 @ 67.45p
10:12 18 @ 68.46p
09:22 1,250 @ 68.46p
08:35 760 @ 68.46p

Skyepharma Key Personnel

CEO Peter Grant

Top of Page